RT Journal Article
SR Electronic
T1 Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.17.20037432
DO 10.1101/2020.03.17.20037432
A1 Chen, Chang
A1 Zhang, Yi
A1 Huang, Jianying
A1 Yin, Ping
A1 Cheng, Zhenshun
A1 Wu, Jianyuan
A1 Chen, Song
A1 Zhang, Yongxi
A1 Chen, Bo
A1 Lu, Mengxin
A1 Luo, Yongwen
A1 Ju, Lingao
A1 Zhang, Jingyi
A1 Wang, Xinghuan
YR 2020
UL http://medrxiv.org/content/early/2020/04/15/2020.03.17.20037432.abstract
AB Background No clinically proven effective antiviral strategy exists for the epidemic Coronavirus Disease 2019 (COVID-19).Methods We conducted a prospective, randomized, controlled, open-label multicenter trial involving adult patients with COVID-19. Patients were randomly assigned in a 1:1 ratio to receive conventional therapy plus Umifenovir (Arbidol) (200mg*3/day) or Favipiravir (1600mg*2/first day followed by 600mg*2/day) for 10 days. The primary outcome was clinical recovery rate of Day 7. Latency to relief for pyrexia and cough, the rate of auxiliary oxygen therapy (AOT) or noninvasive mechanical ventilation (NMV) were the secondary outcomes. Safety data were collected for 17 days.Results 240 enrolled COVID-19 patients underwent randomization; 120 patients were assigned to receive Favipiravir (116 assessed), and 120 to receive Arbidol (120 assessed). Clinical recovery rate of Day 7 does not significantly differ between Favipiravir group (71/116) and Arbidol group (62/120) (P=0.1396, difference of recovery rate: 0.0954; 95% CI: -0.0305 to 0.2213). Favipiravir led to shorter latencies to relief for both pyrexia (difference: 1.70 days, P<0.0001) and cough (difference: 1.75 days, P<0.0001). No difference was observed of AOT or NMV rate (both P>0.05). The most frequently observed Favipiravir-associated adverse event was raised serum uric acid (16/116, OR: 5.52, P=0.0014).Conclusions Among patients with COVID-19, Favipiravir, compared to Arbidol, did not significantly improve the clinically recovery rate at Day 7. Favipiravir significantly improved the latency to relief for pyrexia and cough. Adverse effects caused Favipiravir are mild and manageable. This trial is registered with Chictr.org.cn (ChiCTR2000030254).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis trial is registered with Chictr.org.cn (ChiCTR2000030254).Funding StatementThis work was supported by the National Key Research and Development Program of China (2020YFC0844400).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWith the permission of the corresponding author, we can provide participant data, statistical analysis.